Stock Price
$19.30
current
Volume
4.1M
shares traded
Analyst price target hikes fuel the rally. Chemours Company (CC) shares surged 9.41% to $19.30 on Tuesday, adding roughly $249 million in market capitalization. The specialty chemicals maker has climbed steadily following a series of bullish analyst revisions over the past three weeks, with three major firms raising their price targets by an average of 24%.
Wall Street turns more optimistic. UBS reiterated its Buy rating on February 23 and lifted its price target to $23 from $18, implying 19% upside from current levels. Goldman Sachs followed on February 25, maintaining Neutral but raising its target to $18 from $14. Most recently, Mizuho reaffirmed Outperform on March 5 and boosted its target to $21 from $17. The upgrades suggest improving sentiment around Chemours’ titanium dioxide and thermal management solutions businesses.
Volume confirms conviction. Trading volume reached 4.14 million shares, running 26% above the 3.28 million average. The elevated activity indicates institutional participation rather than retail-driven momentum, lending credibility to the move. Chemours’ $2.90 billion market cap positions it as a mid-cap play in the Basic Materials sector.
What to Watch: Chemours will report Q1 2026 earnings in late April. Investors should monitor whether management commentary supports the Street’s upgraded outlook, particularly around pricing power in titanium dioxide markets and demand trends in semiconductor thermal solutions.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
